Dyne Therapeutics, Inc. DYN
17.36 USD -1.18 (-6.36%)
At closeNov 5, 2026, 4:44 PM EST
17.15 -0.21 -1.21%
After hours · Nov 5, 4:44 PM ET
17.33 Day range 18.78
14.25 52-week range 26.78
- YTD
- -11.25%
- 1 year
- -16.94%
- Market cap
- 3.24B
- EPS (ttm)
- -3.09
- Shares out
- 186.75M
- Forward P/E
- -5.60
- YTD return
- -11.25%
- 1-year return
- -16.94%
- Volume
- 3.20M
- Avg volume
- 2.81M
- Open
- 18.78
- Previous close
- 18.54
- Day's range
- 17.33 – 18.78
- 52-week range
- 14.25 – 26.78
- Beta
- 1.21
- Analysts
- Strong Buy
- Price target
- 34.33 (+97.8%)
- Earnings date
- Mar 4, 2027
5D +0.25 (+1.46%)
Key statistics
- Enterprise value
- 2.71B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -317.14M
- Total cash
- 898.48M
- Total debt
- 233.35M
- Return on equity
- -81.57%
- Short % of float
- 17.44%
- 50-day average
- 18.20
- 200-day average
- 19.32
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 34.33 +97.8% upside
Now 17.36
- Target (low)
- 10.00
- Target (mean)
- 34.33
- Target (high)
- 50.00
Ratings (0m) 17 15 buy · 1 hold · 1 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell1
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate -0.88189.
Financials — quick view
DYN Revenue — quarterly 0
DYN Net income — quarterly -178.56M
DYN EPS — quarterly -1.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | -0.91915 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.90728 | -1.06 | -0.15 | -16.83% |
| Jul 30, 2026 | Jun 30, 2026 | -0.74878 | -1.08 | -0.33 | -44.23% |
| May 11, 2026 | Mar 31, 2026 | -0.77229 | -0.73 | +0.04 | +5.48% |
| Mar 2, 2026 | Dec 31, 2025 | -0.74 | -0.76 | -0.02 | -2.70% |
| Nov 5, 2025 | Sep 30, 2025 | -0.81 | -0.76 | +0.05 | +6.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | down | Outperform | Perform |
| Sep 30, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 30, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 29, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | JP Morgan | down | Neutral | Underweight |
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dyne-tx.com
News
Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate 
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights 
Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session 
Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket 
Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15 
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32 - Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Your note
Sign in to keep a note on DYN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BESKROVNAYA OXANA | Officer | Sale | Mar 10, 2025 | 195,840 |
| COX JOHN | Chief Executive Officer | Sale | Sep 7, 2026 | 429,507 |
| FRIEDL-NADERER JOHANNA | Officer | Sale | Sep 7, 2026 | 152,897 |
| KERR DOUGLAS | Officer | Stock Award(Grant) | Oct 19, 2026 | 170,564 |
| KERSTEN DIRK | Director | Sale | Jul 26, 2026 | 0 |
| LUBNER DAVID CHARLES | Director | Stock Gift | Apr 23, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.55% | 30,912,287 | 573.11M | Jun 29, 2026 |
| Blackrock Inc. | 6.64% | 12,404,330 | 229.98M | Jun 29, 2026 |
| Jupiter Topco LLC | 6.42% | 11,997,738 | 222.44M | Jun 29, 2026 |
| FMR, LLC | 6.00% | 11,207,000 | 207.78M | Jun 29, 2026 |
| State Street Corporation | 3.99% | 7,458,263 | 138.28M | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 3.75% | 7,006,542 | 129.90M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3.75% | 7,004,602 | 129.87M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 2.46% | 4,602,629 | 85.33M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.39% | 4,471,727 | 82.91M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.33% | 4,349,704 | 80.64M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.13% | 3,986,208 | 73.90M | Sep 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 2.04% | 3,809,721 | 70.63M | Jun 29, 2026 |